TauRx is currently conducting a Phase 3 clinical trial, named
LUCIDITY. In collaboration with neurologists and clinical research centres in North America and Europe, this trial has been designed to confirm efficacy of our lead compound after previous results established that this drug has concentration dependent pharmacological action at low dose. We expanded the trial to provide for a broader range of patients, including those
diagnosed with moderate Alzheimer’s disease, to be eligible. Patient recruitment for the trial is complete, and the trial is now closed to screening.
The trial uses well accepted cognitive and
functional assessment scales to confirm the potential benefits seen with our drug in delaying the progression of
Alzheimer’s disease, and includes an open-label phase during which all
participants will receive the drug. Patients completing the full trial will also be eligible for continued use of the drug under an Expanded Access Programme.
Additional information on the study is available via this link.
TauRx has already completed three separate Phase 3 trials: two in Alzheimer's disease and
one in the rare neurodegenerative disorder, behavioural variant
frontotemporal dementia (bvFTD).
Of course, patient safety is our highest priority, and we are working closely with all sites to maintain patient safety in light of the Covid-19 pandemic.